Reach Us +1-217-403-9671
Immunological Aspects Of Formation Of Anti-drug Antibodies Against Aggregated Protein Drugs | 8183
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Immunological aspects of formation of anti-drug antibodies against aggregated protein drugs

International Conference and Exhibition on Biowaivers & Biosimilars

Melody Sauerborn

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.002

I mmunogenicity of protein drugs is a major issue and in recent years it became clear that aggregation plays an important role in initiating an adverse immune response. Since then new analytical tools have been implemented in drug development processes to detect and characterize drug aggregates. Besides analytical tools, industry uses biological tools such as in silico, in vitro and in vivo to predict immunogenicity of protein drugs. This presentation gives an overview about why aggregates are immunogenic, how they trigger the immune response, how we can measure aggregates and their impact on the immune system and new methods on how to prevent aggregation.
Sauerborn spent most of her undergrad years in well-known institutes such as the Centers for Disease Control and Prevention in Atlanta to widen her knowledge in immunology. After acquiring her Masters in Science she joined the lab of Prof. Schellekens and Prof. Jiskoot, two experts in immunogenicity of protein drugs, to shed more light on the immunological aspects of antibody formation against aggregated protein therapeutics. After obtaining her PhD she started a spin-off, ADA InVivo BV, a biotech CRO in the field of drug safety. Currently she is a project leader at the bioanalysis and immunogenicity department at TNO Triskelion BV, a Dutch CRO.
Relevant Topics